A phase 1/2 study of NS-87/CPX-351 (cytarabine and daunorubicin liposome) in Japanese patients with high-risk acute myeloid leukemia.

MLA

Usuki, Kensuke, et al. “A Phase 1/2 Study of NS-87/CPX-351 (Cytarabine and Daunorubicin Liposome) in Japanese Patients with High-Risk Acute Myeloid Leukemia.” International Journal of Hematology, vol. 119, no. 6, June 2024, pp. 647–59. EBSCOhost, https://doi.org/10.1007/s12185-024-03733-z.

APA

Usuki, K., Miyamoto, T., Yamauchi, T., Ando, K., Ogawa, Y., Onozawa, M., Yamauchi, T., Kiyoi, H., Yokota, A., Ikezoe, T., Katsuoka, Y., Takada, S., Aotsuka, N., Morita, Y., Ishikawa, T., Asada, N., Ota, S., Dohi, A., Morimoto, K., & Imai, S. (2024). A phase 1/2 study of NS-87/CPX-351 (cytarabine and daunorubicin liposome) in Japanese patients with high-risk acute myeloid leukemia. International Journal of Hematology, 119(6), 647–659. https://doi.org/10.1007/s12185-024-03733-z

Chicago

Usuki, Kensuke, Toshihiro Miyamoto, Takuji Yamauchi, Kiyoshi Ando, Yoshiaki Ogawa, Masahiro Onozawa, Takahiro Yamauchi, et al. 2024. “A Phase 1/2 Study of NS-87/CPX-351 (Cytarabine and Daunorubicin Liposome) in Japanese Patients with High-Risk Acute Myeloid Leukemia.” International Journal of Hematology 119 (6): 647–59. doi:10.1007/s12185-024-03733-z.